Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nippon Kayaku To Start Cancer Drug NK102’s U.S. Phase II Trial

This article was originally published in PharmAsia News

Executive Summary

Nippon Kayaku plans to start a Phase II trial for cancer drug NK102 in the U.S. this spring. The trial targets intractable breast cancer patients and the selection of the trial facility has entered the final stage. NK102 is developed on a new drug delivery system that encapsulates active metabolite of cancer drug camptothecin with polymer micelle. According to the company, the drug's Phase I trial started in January 2007 in the U.S. showed promising results. The company has set developing polymer micelle cancer drug as a priority, and currently stomach cancer drug NK105 (paclitaxel) and pancreatic drug NK911 (doxorubicin) are in Phase II trials in Japan. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel